Stepronin

Drug Profile

Stepronin

Alternative Names: Broncoplus; KY 01; Masor; Mucodil; Prostenoglycine; Tenoglycine; TS 5010680; TTPG

Latest Information Update: 23 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sigma-tau SpA
  • Developer GlaxoSmithKline; Kissei Pharmaceutical; Pierrel; Samil; Samjin Pharmaceutical Company; sigma-tau SpA
  • Class Amino acids; Antitussives; Expectorants
  • Mechanism of Action HIV replication inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bronchitis; Otorhinolaryngological infections
  • Discontinued Autoimmune disorders; Graft-versus-host disease; HIV infections; Transplant rejection

Most Recent Events

  • 27 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 23 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline
  • 20 Jan 2000 Preclinical development for HIV infections treatment in Italy (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top